PATENT CLAIM ANALYSIS

Application Number: 16038924
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-02
Patent Classification: ["514", "249000"]

Abstract:
The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

Claim (Index 4):
The method of  claim 1 , wherein:\n X is CR X ; Ring A is phenyl optionally substituted by 1 or 2 substituents independently selected from R A ; Ring B is phenyl; 5-10 membered heteroaryl comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O, and S; C 3-7  cycloalkyl; or 4-10 membered heterocycloalkyl comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O, and S; wherein said phenyl, 5-10 membered heteroaryl, C 3-7  cycloalkyl, and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2, 3, or 4 substituents independently selected from R B ; R 1  is OR a1 ; R 3  is H; R 4  is H; each R A  is independently selected from halo, CN, and NO 2 ; each R B  is independently selected from Cy 4 , halo, C 1-6  alkyl, \u2550O, and C(O)OR a5 , wherein said C 1-6  alkyl is optionally substituted by Cy 4 ; R X  is H; each Cy 4  is independently selected from C 3-7  cycloalkyl and 4-7 membered heterocycloalkyl, each of which is optionally substituted with 1 or 2 substituents independently selected from R Cy ; each Cy 5  is independently selected from 4-7 membered heterocycloalkyl optionally substituted with 1 or 2 substituents independently selected from R Cy ; each R Cy  is selected from halo, C 1-4  alkyl, C 1-4  haloalkyl, C 1-4  cyanoalkyl, C 2-6  alkenyl, C 2-6  alkynyl, oxo, CN, NO 2 , OR a6 , SR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O)OR a6 , NR c6 R d6 , NR c6 C(O)R b6 , S(O) 2 R b6 , and S(O) 2 NR c6 R d6 , wherein said C 1-4  alkyl, C 2-6  alkenyl, and C 2-6  alkynyl are each optionally substituted by 1 or 2 substituents independently selected from halo, CN, NO 2 , OR a6 , SR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O)OR a6 , NR c6 R d6 , NR c6 C(O)R b6 , S(O) 2 R b6 , and S(O) 2 NR c6 R d6 ; each R a1  is independently selected from C 1-3  alkyl optionally substituted with 1 or 2 substituents independently selected from Cy 5 ; and each R a5  is independently selected from H, C 1-6  alkyl, C 1-4  haloalkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 6-10  aryl, C 3-10  cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10  aryl-C 1-4  alkyl-, C 3-10  cycloalkyl-C 1-4  alkyl-, (5-10 membered heteroaryl)-C 1-4  alkyl-, and (4-10 membered heterocycloalkyl)-C 1-4  alkyl-, wherein said C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 6-10  aryl, C 3-10  cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10  aryl-C 1-4  alkyl-, C 3-10  cycloalkyl-C 1-4  alkyl-, (5-10 membered heteroaryl)-C 1-4  alkyl-, and (4-10 membered heterocycloalkyl)-C 1-4  alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C 1-4  alkyl, C 1-4  haloalkyl, C 1-4  cyanoalkyl, halo, CN, OR a8 , SR a8 , C(O)R b8 , C(O)NR c8 R d8 , C(O)OR a8 , OC(O)R b8 , OC(O)NR c8 R d8 , NR c8 R d8 , NR c8 C(O)R b8 , NR c8 C(O)NR c8 R d8 , NR c8 C(O)OR a8 , C(\u2550NR e8 )NR c8 R d8 , NR c8 C(\u2550NR e8 )NR c8 R d8 , S(O)R b8 , S(O)NR c8 R d8 , S(O) 2 R b8 , NR c8 S(O) 2 R b8 , NR c8 S(O) 2 NR c8 R d8 , and S(O) 2 NR c8 R d8 ; or any R c5  and R d5  together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C 1-6  alkyl, C 3-7  cycloalkyl, 4-7 membered heterocycloalkyl, C 6-10  aryl, 5-6 membered heteroaryl, C 1-6  haloalkyl, halo, CN, OR a8 , SR a8 , C(O)R b8 , C(O)NR c8 R d8 , C(O)OR a8 , OC(O)R b8 , OC(O)NR c8 R d8 , NR c8 R d8 , NR c8 C(O)R b8 , NR c8 C(O)NR c8 R d8 , NR c8 C(O)OR a8 , C(\u2550NR e8 )NR c8 R d8 , NR c8 C(\u2550NR e8 )NR c8 R d8 , S(O)R b8 , S(O)NR c8 R d8 , S(O) 2 R b8 , NR c8 S(O) 2 R b8 , NR c8 S(O) 2 NR c8 R d8 , and S(O) 2 NR c8 R d8 , wherein said C 1-6  alkyl, C 3-7  cycloalkyl, 4-7 membered heterocycloalkyl, C 6-10  aryl, and 5-6 membered heteroaryl are each optionally substituted by 1, 2, or 3 substituents independently selected from halo, C 1-4  alkyl, C 1-4  haloalkyl, C 1-4  cyanoalkyl, CN, OR a8 , SR a8 , C(O)R b8 , C(O)NR c8 R d8 , C(O)OR a8 , OC(O)R b8 , OC(O)NR c8 R d8 , NR c8 R d8 , NR c8 C(O)R b8 , NR c8 C(O)NR c8 R d8 , NR c8 C(O)OR a8 , C(\u2550NR e8 )NR c8 R d8 , NR c8 C(\u2550NR e8 )NR c8 R d8 , S(O)R b8 , S(O)NR c8 R d8 , S(O) 2 R b8 , NR c8 S(O) 2 R b8 , NR c8 S(O) 2 NR c8 R d8 , and S(O) 2 NR c8 R d8 .

Metadata:
- Claim Count in Document: 61.0
- Percentile: 95.0
- Lexical Diversity: 1.16216
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15610015', '14795536', '14795532', '15670094', '14795466']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8175706054799661
- 35 USC 102 Novelty (BERT): 0.6935668565962139
- Combined Prediction Score: 0.8051702305915909
- Mean Citation Score: 611.988482
- Max Citation Score: 707.0113
- Similarity Product: 691.4217688002587

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test